- Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX
- Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
- Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress
- Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
- Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
- Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
- Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
More ▼
Key statistics
On Friday, Mirum Pharmaceuticals Inc (MIRM:NMQ) closed at 34.43, -3.18% below its 52-week high of 35.56, set on Dec 15, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 33.74 |
---|---|
High | 34.50 |
Low | 33.64 |
Bid | 33.16 |
Offer | 35.53 |
Previous close | 33.88 |
Average volume | 924.93k |
---|---|
Shares outstanding | 47.13m |
Free float | 45.96m |
P/E (TTM) | -- |
Market cap | 1.60bn USD |
EPS (TTM) | -3.82 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:00 BST.
More ▼